Meningococcal vaccines

References

1. Gotschlich EC, Liu TY, Artenstein MS. Human immunity to the meningococcus. Ill Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides. J Exp Med 1969; 129:1349–1365
   [Google Scholar]
2. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV Immunogenicity of the group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969; 129:1367–1384
   [Google Scholar]
3. Gold R, Artenstein MS. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-1970. Bull WHO 1971; 45:279–282
   [Google Scholar]
4. Wahdan MH, Rizk F, El-Akkad AM. et al. A controlled field trial of a serograph A meningococcal polysaccharide vaccine. Bull WHO 1973; 48:667–673
   [Google Scholar]
5. Erwa HH, Hasseeb MA, Idris AA, Lapeyssonnie S, Sanborn WR, Sippel JE. A serogroup A meningococcal polysaccharide vaccine. Studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A. Bull WHO 1973; 49:301–305
   [Google Scholar]
6. Peltola H, Makela PH, Kayhty H. et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977; 297:686–691
   [Google Scholar]
7. Ambrosch F, Wiedermann G, Crooy P, George AM. Imm unogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine. Bull WHO 1983; 61:317–323
   [Google Scholar]
8. Gotschlich EC, Austrian RC, Cvjetanoić B, Robbins JB. Prospects for the prevention of bacterial meningitis with polysaccharide vaccines. Bull WHO 1978; 56:509–518
   [Google Scholar]
9. Greenwood BM, Wali SS. Control of meningococcal infection in the African meningitis belt by selective vaccination. Lancet 1980; 1:729–732
   [Google Scholar]
10. Eskola J, Kàhty H, Takala AK. et al. A randomized prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990; 323:1381–1387
    [Google Scholar]
11. Santosham M, Wolff M, Reid R. et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324:1767–1772
    [Google Scholar]
12. Nazareth B, Slack MPE, Howard AJ, Waight PA, Begg NT. A survey of invasive Haemophilus influenzae infections. CDR Review 1992; 2: No. 2R13–R16
    [Google Scholar]
13. Skevakis L, Frasch CE, Zahradnik JM, Dolin R. Class-specific human bactericidal antibodies to capsular and noncapsular surface antigens of Neisseria meningitidis. J Infect Dis 1984; 149:387–396
    [Google Scholar]
14. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysyalic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138:4402–1407
    [Google Scholar]
15. Zollinger WD, Boslego J, Moran E. et al.(Chilean National Committee for Meningococcal Disease) Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. NIPH Annals 1991; 14: No. 2211–212
    [Google Scholar]
16. Sierra VG, Gampa H, Garcia I, Sotolongo P. Efficacy evalu ation of the Cuban vaccine VA-MENGOC-BC against disease caused by serogroup B Neisseria meningitidis. In: Achtman M. et al. (eds) Neisseria 1990 Berlin: de Gruyter and Co; 1991129–134
    [Google Scholar]
17. Costa W, Saachi CT, Ramos S, Milagnes L, Prigenzi LS. Meningococcal disease in Sao Paulo, Brazil. NIPH Annals 1991; 14:215–216
    [Google Scholar]
18. de Moraes JC, Perkins BA, Camargo MCC. et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340:1074–1078
    [Google Scholar]
19. Bjune G, Hoiby EA, Gronnesby JK. et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093–1096
    [Google Scholar]
20. Munkley A, Tinsley CR, Virji M, Heckels JE. Blocking of bactericidal killing of Neisseria meningitidis by antibodies directed against class 4 outer-membrane protein. Microb Pathog 1991; 11:447–452
    [Google Scholar]
21. Veheul AFM, Braat AK, Leenhouts JM. et al. Preparation, characterization and immunogenicity of meningococcal immunotype L2 and L3, 7, 9, phosphoethaneolamine group-containing oligosaccharide-protein conjugates. Infect Immun 1991; 59:843–851
    [Google Scholar]
22. Jones DM, Borrow R, Fox AJ, Gray S, Cartwright KAV, Poolman JT. The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb Pathog 1992 (in press)
    [Google Scholar]
23. Jennings HJ, Gamian A, Michon F, Ashton FE. Unique intermolecular bactericidal epitope involving the homosi-alopolysaccharide capsule on the cell surface of group B Neisseria meningitidis and Escherichia coli Kl. J Immunol 1989; 142:3585–3591
    [Google Scholar]
24. Devi SJN, Robbins JB, Schneerson R. Antibodies to poly[2-8)-α-N-acetylneuraminic acid] and poly[2-9)-α-N-acetyl-neuraminic acid] are elicited by immunization of mice with <Escherichia coli> K92 conjugates.: potential vaccines for groups B and C meningococci and E. coli K1. Proc. Natl Acad Sci USA 1991; 88:7175–7179
    [Google Scholar]